VJOncology is committed to improving our service to you

ESMO 2019 | REACH safety data: avelumab plus RT-cetuximab in LA SCCHN

VJOncology is committed to improving our service to you

Jean Bourhis

Jean Bourhis, MD, PhD, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland, speaks at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain. Dr Bourhis discusses the safety and toxicity seen in the REACH study (NCT02999087) – a trial evaluating the use of avelumab when combined with cetuximab and radiation therapy in locally advanced squamous cell carcinoma of the head and neck (LA SCCHN).

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter